Net Income (Loss) Attributable to Parent in USD of Aquestive Therapeutics, Inc. from Q1 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Aquestive Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2017 to Q3 2025.
  • Aquestive Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$15,446,000.000, a 34.2% decline year-over-year.
  • Aquestive Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$68,979,000.000, a 96% decline year-over-year.
  • Aquestive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$44,137,000.000, a 461% decline from 2023.
  • Aquestive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$7,870,000.000, a 85.5% increase from 2022.
  • Aquestive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$54,410,000.000, a 22.9% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Aquestive Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$68,979,000 -$15,446,000 -$3,937,000 -34.2% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025
Q2 2025 -$65,042,000 -$13,548,000 -$10,803,000 -3.9% 01 Apr 2025 30 Jun 2025 10-Q 05 Nov 2025
Q1 2025 -$54,239,000 -$22,930,000 -$10,102,000 -78.8% 01 Jan 2025 31 Mar 2025 10-Q 05 Nov 2025
Q4 2024 -$44,137,000 -$17,055,000 -$8,944,000 -1.1% 01 Oct 2024 31 Dec 2024 10-K 05 Mar 2025
Q3 2024 -$35,193,000 -$11,509,000 -$9,474,000 -4.7% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025
Q2 2024 -$25,719,000 -$2,745,000 +$3,047,000 +52.6% 01 Apr 2024 30 Jun 2024 10-Q 05 Nov 2025
Q1 2024 -$28,766,000 -$12,828,000 -$20,896,000 -2.6% 01 Jan 2024 31 Mar 2024 10-Q 05 Nov 2025
Q4 2023 -$7,870,000 -$8,111,000 +$4,241,000 +34.3% 01 Oct 2023 31 Dec 2023 10-K 05 Mar 2025
Q3 2023 -$12,111,000 -$2,035,000 +$10,501,000 +83.8% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024
Q2 2023 -$22,612,000 -$5,792,000 +$10,510,000 +64.5% 01 Apr 2023 30 Jun 2023 10-Q 04 Nov 2024
Q1 2023 -$33,122,000 $8,068,000 +$21,288,000 01 Jan 2023 31 Mar 2023 10-Q 04 Nov 2024
Q4 2022 -$54,410,000 -$12,352,000 +$16,593,000 +57.3% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024
Q3 2022 -$71,003,000 -$12,536,000 +$2,019,000 +13.9% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023
Q2 2022 -$73,022,000 -$16,302,000 -$3,935,000 -31.8% 01 Apr 2022 30 Jun 2022 10-Q 06 Nov 2023
Q1 2022 -$69,087,000 -$13,220,000 +$1,452,000 +9.9% 01 Jan 2022 31 Mar 2022 10-Q 06 Nov 2023
Q4 2021 -$70,539,000 -$28,945,000 -$8,577,000 -42.1% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 -$61,962,000 -$14,555,000 +$1,996,000 +12.1% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022
Q2 2021 -$63,958,000 -$12,367,000 -$10,033,000 -4.3% 01 Apr 2021 30 Jun 2021 10-Q 01 Nov 2022
Q1 2021 -$53,925,000 -$14,672,000 +$1,858,000 +11.2% 01 Jan 2021 31 Mar 2021 10-Q 01 Nov 2022
Q4 2020 -$55,783,000 -$20,368,000 -$7,732,000 -61.2% 01 Oct 2020 31 Dec 2020 10-K 09 Mar 2021
Q3 2020 -$48,051,000 -$16,551,000 +$1,861,000 +10.1% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021
Q2 2020 -$49,912,000 -$2,334,000 +$18,138,000 +88.6% 01 Apr 2020 30 Jun 2020 10-Q 02 Nov 2021
Q1 2020 -$68,050,000 -$16,530,000 -$1,804,000 -12.2% 01 Jan 2020 31 Mar 2020 10-Q 02 Nov 2021
Q4 2019 -$66,246,000 -$12,636,000 +$1,308,000 +9.4% 01 Oct 2019 31 Dec 2019 10-K 09 Mar 2021
Q3 2019 -$67,554,000 -$18,412,000 -$3,374,000 -22.4% 01 Jul 2019 30 Sep 2019 10-K 09 Mar 2021
Q2 2019 -$64,180,000 -$20,472,000 +$16,021,000 +43.9% 01 Apr 2019 30 Jun 2019 10-K 09 Mar 2021
Q1 2019 -$80,201,000 -$14,726,000 -$18,825,000 -4.6% 01 Jan 2019 31 Mar 2019 10-K 09 Mar 2021
Q4 2018 -$61,376,000 -$13,944,000 -$3,904,000 -38.9% 01 Oct 2018 31 Dec 2018 10-K 11 Mar 2020
Q3 2018 -$57,472,000 -$15,038,000 -$23,489,000 -2.8% 01 Jul 2018 30 Sep 2018 10-K 11 Mar 2020
Q2 2018 -$33,983,000 -$36,493,000 -$30,596,000 -5.2% 01 Apr 2018 30 Jun 2018 10-K 11 Mar 2020
Q1 2018 -$3,387,000 $4,099,000 +$5,556,000 01 Jan 2018 31 Mar 2018 10-K 11 Mar 2020
Q4 2017 -$8,943,000 -$10,040,000 01 Oct 2017 31 Dec 2017 10-K 14 Mar 2019
Q3 2017 $8,451,000 01 Jul 2017 30 Sep 2017 10-K 14 Mar 2019
Q2 2017 -$5,897,000 01 Apr 2017 30 Jun 2017 10-K 14 Mar 2019
Q1 2017 -$1,457,000 01 Jan 2017 31 Mar 2017 10-K 14 Mar 2019

Aquestive Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$44,137,000 -$36,267,000 -4.6% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2025
2023 -$7,870,000 +$46,540,000 +85.5% 01 Jan 2023 31 Dec 2023 10-K 05 Mar 2025
2022 -$54,410,000 +$16,129,000 +22.9% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024
2021 -$70,539,000 -$14,756,000 -26.5% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
2020 -$55,783,000 +$10,463,000 +15.8% 01 Jan 2020 31 Dec 2020 10-K 08 Mar 2022
2019 -$66,246,000 -$4,870,000 -7.9% 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021
2018 -$61,376,000 -$52,433,000 -5.9% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2020
2017 -$8,943,000 01 Jan 2017 31 Dec 2017 10-K 14 Mar 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.